Atlas Trials

Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)

Clinical trial NCT00161993 · COMPLETED

Trial details

NCT number
NCT00161993
Sponsor
Baxalta now part of Shire
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Primary Immunodeficiency Diseases (PID)AgammaglobulinemiaHypogammaglobulinemia
Start date
2002-06-13
Primary completion
2003-09-24
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.